An interventional study of Targeted Shiatsu in Cardiac Amyloidosis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 13th largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2024, is one of 10 with no phase, reaches primary completion later than 4 of the 15 other live ones, and was the 27th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in France, United States, Argentina and 21 more countries
Ages 18–75
Gérond'if · Sites in France
Ages 80+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 128 across the 23 interventional studies, 175 across the 12 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 35 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 3 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
5 of the studies in Amyloid Neuropathies, Familial with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05103943Centre Hospitalier Régional d'OrléansAmyloidosis TTR Flow Reserve Evaluation | 2026-12-11 |
| NCT04849754GCS Ramsay Santé pour l'Enseignement et la RechercheAnalysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy | 2026-12-31 |
| NCT04535349University Hospital, CaenQuantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis | 2027-06-15 |
| NCT05101304Saving Lives MattersRegistre HEAR, Healthcare European Amyloidosis Registry | 2027-06-30 |
| NCT06427304Gérond'ifCardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure | 2027-07-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the beneficial effects of three targeted Shiatsu sessions compared to "comfort" Shiatsu on symptoms in patients with severe cardiac amyloidosis. Specifically, the study aims to evaluate the short-term impact of a targeted Shiatsu session on neuro-cardiovascular physiological parameters and symptoms in patients with cardiac amyloidosis, in comparison to comfort Shiatsu and no Shiatsu. Additionally, the study will investigate the effects of three targeted Shiatsu sessions versus "comfort" Shiatsu and no Shiatsu on various symptoms (fatigue, sleep disturbances, pain, anxiety, depression, dyspnea, digestive disorders, nausea) and quality of life in cardiac amyloidosis patients with severe symptoms. Patient satisfaction with Shiatsu will also be evaluated, alongside an assessment of the tolerance to Shiatsu.
IAmyloidosis leads to a wide range of disorders, including vascular, cardiac, neuropathic, digestive, renal, and others. These impairments significantly affect patients' quality of life, autonomy, and are often accompanied by stress and anxiety. Literature reviews indicate that complementary approaches have a positive impact on alleviating the symptoms of disabling chronic illnesses, with Shiatsu showing efficacy in several international studies. As part of an initiative to improve patient care and better address their chronic, persistent symptoms, we propose incorporating Shiatsu targeted specifically at amyloidosis symptoms as a complementary therapy. How can Shiatsu help patients with amyloidosis? What impact does it have on their quality of life and various symptoms?
Hypothesis/Objective:
This study aims to demonstrate the beneficial impact of three targeted Shiatsu sessions compared to "comfort" Shiatsu on symptoms in cardiac amyloidosis patients with severe symptoms. Additionally, it will assess the short-term effects of a targeted Shiatsu session on neuro-cardiovascular physiological parameters and symptoms in cardiac amyloidosis patients, comparing the effects of targeted Shiatsu, comfort Shiatsu, and no Shiatsu. The study will evaluate the impact of these interventions on symptoms such as fatigue, sleep disturbances, pain, anxiety, depression, dyspnea, digestive disorders, and nausea, as well as the overall quality of life. It will also assess patient satisfaction with Shiatsu and evaluate the therapy's tolerance.
Method:
This is a randomized, controlled, superiority, single-center, double-blind study comparing the effects of "targeted" Shiatsu sessions on amyloidosis symptoms with those of "comfort" (non-targeted) Shiatsu sessions.
Population:
The study will involve patients diagnosed with amyloidosis (TTR, WT, AL) who are hospitalized or followed at the Centre de Référence Amyloses-Cardiaques (Cardiogen branch) at the CHU Henri Mondor in Créteil, France. A total of 108 patients will participate: 78 in the Shiatsu group (26 AL, 26 TTR, 26 WT), 39 in the Comfort Shiatsu group, 39 in the Targeted Shiatsu group, and 30 in the No Shiatsu group. The expected inclusion rate per center per month is 4.5, with a study duration of 2 years.
Primary Endpoint:
Reduction in total ESAS symptom score 48 hours after the third Shiatsu session.
Secondary Endpoints:
A 20% improvement in heart rate variability measured with the e-patch. A 20% improvement in skin conductance and variability measured with the SUDOSCAN.
Overall score on the EQ-5D scale. Overall score on the MINNESOTA scale. A 2-point improvement in the symptom-specific questionnaire corresponding to the symptom targeted by Shiatsu (e.g., dyspnea, digestive disorders, pain).
Improvement in at least one global score on the BFI, HADS, or LSEQ scales.
Inclusion Visit (D0):
Patients will be offered participation during their routine care consultation. Once consent is obtained, the patient will complete several questionnaires (MINNESOTA, EESE-R, EQ-5D, QCD, BFI, LSEQ, HADS). Measurements with the SUDOSCAN will be taken, and the e-patch will be applied for 48 hours. For Shiatsu participants, randomization will be conducted by an open-label CRA independent of the study, and the results will be sent to the Shiatsu specialists (targeted or comfort). The patient will then receive a Shiatsu session accordingly.
Research Follow-Up Visits:
Visit 1 (D1): A second SUDOSCAN measurement will be taken 24 hours post-Shiatsu session or inclusion for the no-Shiatsu group. Follow-up measurements will be taken at 24 and 48 hours.
Visit 2 (D2): A third SUDOSCAN measurement will be taken 48 hours post-Shiatsu or inclusion. Patients will complete the EESE-R and modified TAQ questionnaires.
Visit 3 (D7±1 day): The Shiatsu group will receive a second Shiatsu session and complete the modified TAQ questionnaire 48 hours later (D9±1 day).
Visit 4 (D14±1 day): The Shiatsu group will receive a third Shiatsu session and complete the modified TAQ questionnaire 48 hours after the session (D16±1 day).
Telephone Visits:
Contact 1 (D16±1 day): Telephone follow-up 48 hours after the third Shiatsu session, during which patients will complete various questionnaires (MINNESOTA, EESE-R, EQ-5D, QCD, BFI, LSEQ, HADS, modified TAQ).
Contact 2 (D31±1 day): A second telephone follow-up to complete the same set of questionnaires.
Conclusion:
The expected benefits for patients include an improvement in quality of life and symptoms (e.g., appetite, nausea, digestive disorders, sleep, fatigue, anxiety, depression, pain) as well as balancing of the autonomic nervous system (ANS), which is often weakened by disease progression and hospitalization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with :
Exclusion Criteria:
Comfort Shiatsu: 39 Targeted Shiatsu: 39
Other: Targeted Shiatsu
patients with cardiac amyloidosis with severe symptoms
Other: Targeted Shiatsu
demonstrate the beneficial impact targeted Shiatsu compared with a "comfort" Shiatsu
EESE-R (ESAS) TOTAL SYMPTOM SCORE AT 48 HOURS AFTER THIRD SHIATSU SESSION
Description of efficacy endpoints for primary endpoint: Reduction in total ESAS symptom score at 48 hours after third shiatsu session. Questionnaire at J0 (before first session) - J2 (48 H after first session)- J16 48H (after third session) - J31 48H (15 days after third session).
Time frame: 31 days ± 1 day
MEASUREMENT PHYSIO, SUDOSCAN, E-PATCH
Description of secondary endpoint: 20% improvement in heart rate variability measured with the e-patch. Continuous measurement \[0-48H\] after first Shiatsu session
Time frame: 48 hours
Plan to share: No — DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Apr 2026, 25 months after the start.
Of 30 interventional studies with no phase under Amyloid Neuropathies, Familial, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's planned 25 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloid Neuropathies, Familial →
Assistance Publique - Hôpitaux de Paris →